# Neurology (multiple sclerosis) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN
- Date: 2026-03-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rafael Lindgren-Achebe, MD
- Calendar frame: modern shifted

- Requested by: Imogen Thackeray-Osei, MD

## Reason for consultation

Suspected demyelinating disease in a 28-year-old professional cellist with three weeks of numbness, loss of position sense and clumsiness in the fingers of both hands, worse on the left, Lhermitte's sign and fatigue, after a similar month of finger tingling 18 months ago. MRI of the brain and cervical and thoracic spine with gadolinium is booked this week. Please see her within two weeks to review the MRI with her, confirm or exclude multiple sclerosis, and plan treatment. **S**

## History

Ms. du Pré, 28, is seen at the request of Dr. Thackeray-Osei two weeks after she presented with numbness and clumsiness of the fingers of both hands, Lhermitte's sign and fatigue. She has since had MRI of the brain and spine with gadolinium and a lumbar puncture. Her fingers are no better: she can practice only a few minutes at a time and has cancelled two more concerts. She recalls a month of finger tingling about 18 months ago that settled without treatment; she has had no visual loss, double vision, imbalance or bladder symptoms. She travels for concerts and teaches. She is not planning a pregnancy this year but would like children in future. **S**

## Examination

| System | Finding |
|---|---|
| Cranial nerves | Normal; no nystagmus; normal acuity, fields and fundi |
| Motor | Strength 5 out of 5 except left finger abduction 4+; tone normal; reflexes brisk in the arms, normal in the legs; plantar responses flexor |
| Sensory | Reduced vibration and joint position sense in the fingers of both hands, worse on the left, with mild pseudoathetosis of the left fingers with the eyes closed; Lhermitte's sign present |
| Coordination and gait | Nine-hole peg test 24.5 seconds right, 31.0 seconds left; finger-nose normal; gait, tandem and Romberg normal. EDSS 2.0 |

BP 114/72 mmHg; pulse 76 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 63.4 kg; BMI 21.2 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Thackeray-Osei's intake note and results. MRI of the brain with gadolinium: eleven ovoid T2 lesions, eight periventricular (several perpendicular to the ventricles), two juxtacortical and one in the right middle cerebellar peduncle; one periventricular lesion enhances; central veins in most lesions. MRI of the cervical and thoracic spine: short dorsal lesion at C3 to C4 with patchy enhancement, non-enhancing lesion at T7, no swelling. Lumbar puncture: white cells 6, protein 42 mg/dL, six CSF-specific oligoclonal bands, IgG index 0.86. Serum aquaporin-4 IgG (cell-based) negative; HIV and syphilis negative; JCV antibody positive, index 1.4. Vitamin B12 468 pg/mL and TSH 1.6 mIU/L at the first visit. Drawn with the lumbar puncture: hepatitis B surface antigen and core antibody negative, surface antibody negative; varicella IgG positive. Today: 25-hydroxyvitamin D 16 ng/mL; IgG 1080 and IgM 124 mg/dL; urine pregnancy test negative. 25-hydroxyvitamin D: 16 ng/mL (low); IgG: 1080 mg/dL; IgM: 124 mg/dL; PHQ-9: 7; GAD-7: 6; Nine-hole peg test, right hand: 24.5 s; Nine-hole peg test, left hand: 31 s. All results are synthetic.

## Assessment

1. **Relapsing-remitting multiple sclerosis, active** (G35.A). Multiple sclerosis by the 2017 McDonald criteria: a current attack of partial cervical myelitis, with dissemination in space in four regions and dissemination in time shown by enhancing and non-enhancing lesions on the same scan; CSF-specific oligoclonal bands add certainty. The 2024 revision is also met, and central veins support the diagnosis. The earlier episode of finger tingling was probably a first attack. Mimics were considered and excluded: normal B12 and thyroid function, negative aquaporin-4 antibody (a cell-based assay is needed for any myelitis), negative HIV and syphilis serology. MOG antibody testing is not indicated: there is no optic neuritis, long cord lesion or ADEM-like illness, and the lesions are typical of MS. With a disabling relapse, an enhancing cord lesion and multiple lesions at 28, her disease is active, and early high-efficacy treatment gives the best long-term outcome. **S**
2. **Vitamin D deficiency** (E55.9). Correct the deficiency; vitamin D is not a treatment for MS. **S**

## Recommendations

1. Treat the relapse, which limits her hand function and her work: methylprednisolone 1 g intravenously daily for 3 days after a negative urine dipstick (oral methylprednisolone 500 mg daily for 5 days is an equivalent alternative).
2. Early high-efficacy disease-modifying therapy with ocrelizumab: 300 mg intravenously on day 1 and day 15, then 600 mg every six months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion. Natalizumab is not advised because her JCV antibody is positive, which raises the risk of PML with longer use; ofatumumab is an equally effective option that she declined in favor of twice-yearly infusions.
3. Before the first infusion: hepatitis B screening (done; not immune), immunoglobulins, varicella and measles immunity, and a pregnancy test; inactivated vaccines at least two weeks before (PCV20, recombinant zoster and hepatitis B started today), and no live vaccines once treatment starts. Check hepatitis B surface antibody one to two months after the series.
4. Re-baseline MRI of the brain three to six months after starting, then yearly; blood count and immunoglobulins before each dose; teach her that infections, especially urinary infections, are more common and can cause a pseudo-relapse that does not need steroids.
5. Occupational therapy for hand function and energy management, and a graded return to practice; aerobic exercise and pacing for fatigue after excluding other causes.
6. Cholecalciferol 4000 units daily for the deficiency, with a level in three months.
7. Pregnancy: contraception for now; when she is ready, a preconception visit, with conception planned a few months after an ocrelizumab dose.
8. Primary care to share the monitoring: blood tests before infusions, vaccinations, infection review, mood and fatigue.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Thackeray-Osei the same day. The MRI and spinal fluid results were shown and explained to Ms. du Pré in plain words, with the good outlook for hand recovery after a first cord relapse and the evidence that early high-efficacy treatment protects long-term function. She chose ocrelizumab. She decides who else receives this note. **S**

## Follow-up

Methylprednisolone from tomorrow; first ocrelizumab infusion in three weeks; neurology review at three months with the re-baseline MRI, then every six months; MS specialist nurse available between visits. **S**

## Guideline basis

- Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018), American Academy of Neurology
- Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018), European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology
- Multiple sclerosis in adults: management (NICE guideline NG220) (2022), National Institute for Health and Care Excellence
- Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17(2):162-173 (PMID 29275977) (2017), The Lancet Neurology
- Montalban X, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol 2025;24(10):850-865 (doi:10.1016/S1474-4422(25)00270-4) (2025), The Lancet Neurology
- Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021), The Lancet Neurology
- Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177-189 (PMID 26092914) (2015), Neurology
- Hauser SL, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376(3):221-234 (PMID 28002679) (2017), New England Journal of Medicine
- Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019), American Academy of Neurology
